Home Cart Sign in  
Chemical Structure| 917389-32-3 Chemical Structure| 917389-32-3

Structure of Letermovir
CAS No.: 917389-32-3

Chemical Structure| 917389-32-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Letermovir (AIC246) is a potent inhibitor of CMV that targets the viral terminase complex and remains effective against virus strains resistant to DNA polymerase inhibitors.

Synonyms: AIC246; MK-8228; Prevymis

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Mulder, Lance ; da Sá, Renata Vieira ; Korsten, Joep ; Freeze, Eline ; Schotting, Amber J ; Koen, Gerrit , et al.

Abstract: Human cytomegalovirus (CMV) infections can cause severe neurological complications, particularly in newborns and immunocompromised patients. Children affected with congenital infection may develop long-term neurological damage and intellectual disabilities. Currently, postnatal therapies are limited and there are no prenatal options available. Research on against congenital infections is, at least partly, restricted due to the lack of physiologically relevant models and the use of lab-adapted strains with limited clinical relevance. In this study, we evaluated the toxicity and efficacy of three FDA-approved anti-CMV drugs against two strains, a clinical and a lab-adapted strain, using two human induced pluripotent stem cell (iPSC-)derived central nervous system models, viz. neural progenitor cells (NPCs) and dorsal forebrain regionalized neural organoids (RNOs). We found iPSC line-dependent differences in toxicity. We observed that treatment restored NPCs and RNOs gene expression after infection and reduced copy numbers. Infection of NPCs and RNOs with the clinical strain, but not with the lab-adapted strain, led to an impaired expression of cortical development markers. Our findings highlight the value of using physiologically relevant human models and clinical strains to understand the neuropathogenesis of congenital and to test therapeutic strategies.

Keywords: congenital ; neural organoids ;

Purchased from AmBeed:

Alternative Products

Product Details of Letermovir

CAS No. :917389-32-3
Formula : C29H28F4N4O4
M.W : 572.55
SMILES Code : FC1=C(N=C(N2CCN(C3=CC=CC(OC)=C3)CC2)N(C4=CC(C(F)(F)F)=CC=C4OC)[C@H]5CC(O)=O)C5=CC=C1
Synonyms :
AIC246; MK-8228; Prevymis
MDL No. :MFCD22572725
InChI Key :FWYSMLBETOMXAG-QHCPKHFHSA-N
Pubchem ID :45138674

Safety of Letermovir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05362916 People Living with HIV ACTIVE_NOT_RECRUITING 2025-12-31 Mcgill University Health Cente... More >>r, Montreal, Quebec, H4A 3J1, Canada Less <<
NCT06575374 Cell Therapy RECRUITING 2027-08-01 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<
NCT06449586 Hematologic Malignancy RECRUITING 2026-06-01 Tongji Hospital of Huazhong Un... More >>iversity of Science and Technology, Wuhan, Wuhan, Hubei, China|Ruijin Hospital of Shanghai Jiaotong University, Shanghai, Shanghai, China|The First Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China|Shanghai Liquan Hospital, Shanghai, China Less <<
NCT05763823 Cytomegalovirus Infection PHASE3 COMPLETED 2024-04-18 Anhui Provincial Hospital ( Si... More >>te 0024), Hefei, Anhui, 230071, China|Peking University First Hospital ( Site 0009), Beijing, Beijing, 100034, China|Peking University People's Hospital-Hematology ( Site 0033), Beijing, Beijing, 100034, China|The Second Affiliated Hospital of Third Military Medical University-Oncology Department ( Site 0002), Chongqing, Chongqing, 400037, China|Southwest Hospital of Third Military Medical University ( Site 0005), Chongqing, Chongqing, 400038, China|The Second Affiliated Hospital Chongqing Medical University ( Site 0013), Chongqing, Chongqing, 400072, China|Guangzhou First People's Hospital-Hematology Department ( Site 0001), Guangzhou, Guangdong, 510180, China|Southern Medical University Nanfang Hospital ( Site 0003), Guangzhou, Guangdong, 510515, China|Shenzhen Second People's Hospital-Hematology Department ( Site 0006), Shenzhen, Guangdong, 518035, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0028), Wuhan, Hubei, 430022, China|Tongji Hospital Tongji Medical,Science & Technology ( Site 0032), Wuhan, Hubei, 430030, China|The First Affiliated Hospital of Soochow University-hematology department ( Site 0029), Suzhou, Jiangsu, 215006, China|The Affiliated Hospital of Xuzhou Medical College ( Site 0022), Xuzhou, Jiangsu, 221006, China|The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0021), Nanchang, Jiangxi, 330209, China|The First Hospital of Jilin University-Hematology ( Site 0023), Changchun, Jilin, 130021, China|The 2nd Affiliated Hospital of Dalian Medical University ( Site 0019), Dalian, Liaoning, 116023, China|Shanghai General Hospital ( Site 0018), Shanghai, Shanghai, 200080, China|West China Hospital, Sichuan University ( Site 0008), Chengdu, Sichuan, 610041, China|The General Hospital of Western Theater Command ( Site 0007), Chengdu, Sichuan, 610083, China|Institute of hematology&blood disease hospital-Hematology ( Site 0030), Tianjin, Tianjin, 300020, China|The First Affiliated Hospital, Zhejiang University ( Site 0025), Hangzhou, Zhejiang, 310003, China Less <<
NCT06441669 Cytomegalovirus Infection Reac... More >>tivation Less << RECRUITING 2026-05-20 Anhui Provincial Hospital, Hef... More >>ei, Anhui, China Less <<
NCT04732260 Pregnant Women Undergoing TOP|... More >>TOP - Failed Attempted Termination of Pregnancy Less << COMPLETED 2021-11-12 H?pital Necker - Enfants malad... More >>es, Paris, 75015, France Less <<
NCT04904614 Cytomegalovirus Disease|Cytome... More >>galovirus Infections|Heart Transplant Infection|Antiviral Toxicity|Neutropenia Less << PHASE4 ACTIVE_NOT_RECRUITING 2025-12-30 Tufts Medical Center, Boston, ... More >>Massachusetts, 02111, United States Less <<
NCT06118515 Congenital Cytomegalovirus Inf... More >>ection Less << PHASE1 RECRUITING 2025-08-31 Children's of Alabama Child He... More >>alth Research Unit (CHRU), Birmingham, Alabama, 35233-0011, United States|Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease, Washington, District of Columbia, 20010-2916, United States|Emory University School of Medicine, Atlanta, Georgia, 30322-1014, United States|University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, 40202, United States|Louisiana State University Health Shreveport - Infectious Diseases, Shreveport, Louisiana, 71101, United States|University of Minnesota - Pediatric Infectious Disease, Minneapolis, Minnesota, 55454, United States|SUNY Upstate Medical University Hospital - Pediatrics, Syracuse, New York, 13210-2342, United States|Nationwide Children's Hospital - Neonatology - Center for Perinatal Research, Columbus, Ohio, 43205-2664, United States|University of Texas Southwestern Medical Center - Pediatrics, Dallas, Texas, 75390-9063, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226-3522, United States Less <<
NCT05656599 CMV Infection|Hematopoietic St... More >>em Cell Transplantation Less << ENROLLING_BY_INVITATION 2025-12-25 Department of Hematology, Peki... More >>ng University People's Hospital, Beijing, Beijing, 100044, China|People's Hospital of Peking University, Beijing, China Less <<
NCT05914675 The Incidence of Peripheral Bl... More >>ood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation Less << PHASE4 NOT_YET_RECRUITING 2024-12-31 -
NCT06407232 Cytomegalovirus Infections|Kid... More >>ney Transplant Infection|Pancreas Transplant Less << PHASE3 RECRUITING 2025-09-26 UW Hospital and Clinics, Madis... More >>on, Wisconsin, 53792, United States Less <<
NCT04312841 B-Cell Prolymphocytic Leukemia... More >>|Chronic Lymphocytic Leukemia|Peripheral T-Cell Lymphoma|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|T-Cell Prolymphocytic Leukemia Less << PHASE2 ACTIVE_NOT_RECRUITING 2024-12-31 Ohio State University Comprehe... More >>nsive Cancer Center, Columbus, Ohio, 43210, United States Less <<
NCT05626530 Cytomegalovirus Infections|Inf... More >>ection in Solid Organ Transplant Recipients|Neutropenia|Antiviral Toxicity Less << PHASE4 RECRUITING 2025-12-15 Tufts Medical Center-Division ... More >>of Geographic Medicine and Infectious Diseases, Boston, Massachusetts, 02111, United States Less <<
NCT06626555 HIV PHASE2 NOT_YET_RECRUITING 2025-03-26 -
NCT05789615 CMV Infection|Hematopoietic St... More >>em Cell Transplantation Less << RECRUITING 2024-12-31 The First Affiliated Hospital ... More >>of Soochow university, Suzhou, Jiangsu, China Less <<
NCT06306989 Letemovir for the Prevention o... More >>f CMV Infection After Allo-HSCT Less << RECRUITING 2025-12-01 Cao, Weijie, Zhengzhou, Henan,... More >> 450000, China Less <<
NCT05969743 Graft-versus-host-disease|CMV PHASE2 NOT_YET_RECRUITING 2025-07-31 -
NCT03728426 Cytomegalovirus Infections PHASE2 COMPLETED 2022-03-28 Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02214, United States|Boston Children's Hospital, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.17mL

8.73mL

1.75mL

0.87mL

17.47mL

3.49mL

1.75mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories